Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations
NCT06029816 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42
Last updated 2023-09-08
Summary
Single-arm, open-label, multicenter phase II clinical study
Conditions
Interventions
- DRUG
-
Neratinib tablets
Neratinib tablets
Sponsors & Collaborators
-
Convalife (Shanghai) Co., Ltd.
lead INDUSTRY
Principal Investigators
-
Wenfeng Fang · Sun Yat-sen University
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-11-20
- Primary Completion
- 2024-12-30
- Completion
- 2025-12-30
Countries
- China
Study Locations
More Related Trials
-
Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers
NCT06585059 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC
NCT04455594 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy
NCT01297101 ·Status: TEMPORARILY_NOT_AVAILABLE
-
Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer
NCT01407822 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression
NCT06269211 ·Status: RECRUITING ·Phase: PHASE2
-
Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC
NCT06863506 ·Status: RECRUITING ·Phase: PHASE2
-
Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC
NCT06709859 ·Status: RECRUITING ·Phase: PHASE2
-
Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC
NCT06300424 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)
NCT03240393 ·Status: WITHDRAWN ·Phase: PHASE2
-
Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers
NCT04946968 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative
NCT03758287 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation
NCT03856697 ·Status: UNKNOWN ·Phase: PHASE3
-
Acquired Resistant Mechanism of the First-generation EGFR TKIs
NCT02804217 ·Status: UNKNOWN
-
Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFR
NCT04785742 ·Status: UNKNOWN ·Phase: PHASE2
-
A Retrospective EGFR Mutation Status Study in Chinese NSCLC Patients Using Paired Plasma and Tissue Samples
NCT01382992 ·Status: UNKNOWN
-
Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)
NCT02006043 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test
NCT02738684 ·Status: UNKNOWN
-
Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg
NCT07298148 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC
NCT02960607 ·Status: UNKNOWN ·Phase: PHASE2
-
Combination of Metformin With Gefitinib to Treat NSCLC
NCT01864681 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer
NCT02535507 ·Status: UNKNOWN ·Phase: PHASE2
-
SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
NCT06080776 ·Status: RECRUITING ·Phase: PHASE3
-
Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations
NCT06062823 ·Status: RECRUITING ·Phase: PHASE2
-
Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer
NCT05003037 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy
NCT02788058 ·Status: UNKNOWN ·Phase: PHASE2